search
Back to results

High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department (HIDO-LIDO)

Primary Purpose

Abdominal Pain, Renal Colic

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Lidocaine Iv
HYDROmorphone Injection
Sponsored by
Hennepin Healthcare Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abdominal Pain focused on measuring lidocaine, hydromorphone, abdominal pain

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be a patient in the emergency department (ED)
  • Must have acute abdominal pain, defined as abdominal or flank pain of a duration of 7 days or less
  • Predicted treatment must include the use of an intravenous opiate

Exclusion Criteria:

  • Cardiac conduction system impairment (QTc duration > 0.5s, QRS duration > 0.12s, PR interval <0.12s or > 0.2s)
  • Known renal (CKD >2) or liver disease (Childs-Pugh B or greater)
  • Hemodynamically instability, defined by the attending physician
  • Pregnant or breastfeeding
  • Have a known allergy to either medication
  • Used of prescription or illicit opioids within the previous week
  • Patients with a chronic pain disorder, defined as use of any analgesic medication on more days than not during the four weeks preceding the acute episode of pain

Sites / Locations

  • Hennepin County Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intravenous Lidocaine

Intravenous Hydromorphone

Arm Description

Administered at a dose of 2 mg/kg over 5 minutes

Administered at a dose of 1 mg over 5 minutes

Outcomes

Primary Outcome Measures

Mean Improvement in Pain at 90 Minutes
The difference between the pain score at time 0 and 90 minutes

Secondary Outcome Measures

Sufficient Pain Relief
Does the patient require off-protocol medication for additional pain relief? Off-protocol defined as any opiate or NSAID
Improvement in Numerical Pain Score at 15 minutes
The difference between the pain score at time 0 and 15 minutes
Improvement in Numerical Pain Score at 30 minutes
The difference between the pain score at time 0 and 30 minutes
Improvement in Numerical Pain Score at 60 minutes
The difference between the pain score at time 0 and 60 minutes
Improvement in Numerical Pain Score at 120 minutes
The difference between the pain score at time 0 and 120 minutes
Improvement in Numerical Pain Score at 150 minutes
The difference between the pain score at time 0 and 150 minutes
Improvement in Numerical Pain Score at 180 minutes
The difference between the pain score at time 0 and 180 minutes
Patient Preference for the Medication They Received
If the patient were to come to the ED again for the same complaint, would they want the same drug they received?
Medication for Side Effects
Are any medications required to control medication side effects, defined as any new symptom after the administration of the study drug.
Side Effects
Yes or no, did the patient have any side effects, defined as any new symptom after the administration of the study drug.
Administration of naloxone
Yes or no, was naloxone required after the patient received the study drug?
Change in Disposition
Yes or no, did the patients disposition change as a consequence of administration of the study drug?
Missed Diagnosis
Yes or no, did the patient have an unplanned return visit to an emergency department resulting in hospital admission?
Serious Adverse Event
Yes or no, did the patient suffer a serious adverse event? Defined as death, requiring or prolonging inpatient hospitalization, resulting in persistent or significant disability/incapacity, or is considered a significant medical event by the investigator based off of medical judgement.

Full Information

First Posted
May 7, 2020
Last Updated
February 23, 2021
Sponsor
Hennepin Healthcare Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04398316
Brief Title
High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department
Acronym
HIDO-LIDO
Official Title
High Dose Intravenous Lidocaine vs Hydromorphone for Acute Abdominal Pain in the Emergency Department: A Randomized, Comparative Efficacy Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Recruiting
Study Start Date
February 18, 2021 (Actual)
Primary Completion Date
February 14, 2022 (Anticipated)
Study Completion Date
April 14, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hennepin Healthcare Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Intravenous lidocaine will be given at a dose of 2 mg/kg intravenously to patients in the emergency department with a diagnosis of acute abdominal pain. Its efficacy will be compared to 1 mg of intravenous hydromorphone, with a primary endpoint of mean improvement of pain at 90 minutes.
Detailed Description
Abdominal pain is a common chief complaint for patients presenting to the emergency department (ED) in the United States. Intravenous opioids are commonly used to treat acute abdominal pain in the ED. These medications are highly efficacious and, when used in a monitored setting such as the ED, extremely safe. Use of opioids has fallen out of favor because of a spike in opioid-related overdose deaths throughout the United States. While use of opioids in the ED is unlikely to contribute to outpatient opioid deaths, minimizing the use of opioids in the ED will contribute to an opioid free culture, in which opioids are used only when absolutely necessary. A variety of different types of medications can be used in lieu of opioids. One such medication, intravenous lidocaine, has been used extensively for neuropathic pain, in the peri- and post-operative surgical setting, the cardiac care unit, and most recently in the emergency department. Intravenous lidocaine has long been used to treat pain. In publications dating back to 1980, intravenous lidocaine has been shown to be an effective treatment for neuropathic pain. In the postoperative setting, intravenous lidocaine decreased pain and decreased the need for opiates. More recently, emergency medicine investigators in Iran demonstrated that intravenous lidocaine decreased pain associated with renal colic and limb ischemia. An ED-based study in the United States showed comparable efficacy between morphine and intravenous lidocaine when used for acute pain. Most recently, a prospective RCT showed 120 mg of intravenous lidocaine was efficacious for abdominal pain, albeit not as effective as 1 mg of hydromorphone. However, a subgroup analysis showed that when lidocaine was dosed at 2 mg/kg, it was equally as effective as hydromorphone. Over the years, intravenous lidocaine has been used for a variety of indications including arrhythmia prophylaxis in patients with acute coronary syndromes. Known side effects of intravenous lidocaine range from transient neurological symptoms (dizziness, paresthesias), to cardiac dysrhythmias and seizure. To date, no deaths have been attributed to its use for treating pain, and the only documented significant complication was due to an unintentional overdose when a patient received ten times the normal dose. All reported side effects in pain patients have been transient and resolved by either stopping the drug, decreasing the infusion rate or by observation alone. Additionally, doses of 2 mg/kg have been tolerated well in the outpatient setting, operating room and ED without any serious side effects. Thus, intravenous lidocaine is an emerging medication for safe and rapid relief of pain, has no known addictive properties, and creates a potential for a pain practice paradigm shift in the United States. We therefore propose a randomized, double blind, comparative efficacy trial to address the following aim: To determine if a 2 mg/kg dose of intravenous lidocaine is as equally efficacious as a single dose of 1 mg intravenous hydromorphone for acute abdominal pain in the emergency department.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Pain, Renal Colic
Keywords
lidocaine, hydromorphone, abdominal pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
187 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intravenous Lidocaine
Arm Type
Experimental
Arm Description
Administered at a dose of 2 mg/kg over 5 minutes
Arm Title
Intravenous Hydromorphone
Arm Type
Active Comparator
Arm Description
Administered at a dose of 1 mg over 5 minutes
Intervention Type
Drug
Intervention Name(s)
Lidocaine Iv
Other Intervention Name(s)
Xylocaine
Intervention Description
2 mg/kg over 5 minutes
Intervention Type
Drug
Intervention Name(s)
HYDROmorphone Injection
Other Intervention Name(s)
Dilaudid
Intervention Description
1 mg over 5 minutes
Primary Outcome Measure Information:
Title
Mean Improvement in Pain at 90 Minutes
Description
The difference between the pain score at time 0 and 90 minutes
Time Frame
90 minutes
Secondary Outcome Measure Information:
Title
Sufficient Pain Relief
Description
Does the patient require off-protocol medication for additional pain relief? Off-protocol defined as any opiate or NSAID
Time Frame
From administration of study drug until patient leaves the emergency department, up until 3 hours from administration of study drug.
Title
Improvement in Numerical Pain Score at 15 minutes
Description
The difference between the pain score at time 0 and 15 minutes
Time Frame
15 minutes
Title
Improvement in Numerical Pain Score at 30 minutes
Description
The difference between the pain score at time 0 and 30 minutes
Time Frame
30 minutes
Title
Improvement in Numerical Pain Score at 60 minutes
Description
The difference between the pain score at time 0 and 60 minutes
Time Frame
60 minutes
Title
Improvement in Numerical Pain Score at 120 minutes
Description
The difference between the pain score at time 0 and 120 minutes
Time Frame
120 minutes
Title
Improvement in Numerical Pain Score at 150 minutes
Description
The difference between the pain score at time 0 and 150 minutes
Time Frame
150 minutes
Title
Improvement in Numerical Pain Score at 180 minutes
Description
The difference between the pain score at time 0 and 180 minutes
Time Frame
180 minutes
Title
Patient Preference for the Medication They Received
Description
If the patient were to come to the ED again for the same complaint, would they want the same drug they received?
Time Frame
Day 7
Title
Medication for Side Effects
Description
Are any medications required to control medication side effects, defined as any new symptom after the administration of the study drug.
Time Frame
15 minutes after administration of study drug then again at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes and 180 minutes
Title
Side Effects
Description
Yes or no, did the patient have any side effects, defined as any new symptom after the administration of the study drug.
Time Frame
15 minutes after administration of study drug then again at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes and at 7 days
Title
Administration of naloxone
Description
Yes or no, was naloxone required after the patient received the study drug?
Time Frame
15 minutes after administration of study drug then again at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes and at 180 minutes
Title
Change in Disposition
Description
Yes or no, did the patients disposition change as a consequence of administration of the study drug?
Time Frame
15 minutes after administration of study drug then again at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes and at 180 minutes
Title
Missed Diagnosis
Description
Yes or no, did the patient have an unplanned return visit to an emergency department resulting in hospital admission?
Time Frame
7 days after administration of study drug
Title
Serious Adverse Event
Description
Yes or no, did the patient suffer a serious adverse event? Defined as death, requiring or prolonging inpatient hospitalization, resulting in persistent or significant disability/incapacity, or is considered a significant medical event by the investigator based off of medical judgement.
Time Frame
180 minutes after administration of study drug

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be a patient in the emergency department (ED) Must have acute abdominal pain, defined as abdominal or flank pain of a duration of 7 days or less Predicted treatment must include the use of an intravenous opiate Exclusion Criteria: Cardiac conduction system impairment (QTc duration > 0.5s, QRS duration > 0.12s, PR interval <0.12s or > 0.2s) Known renal (CKD >2) or liver disease (Childs-Pugh B or greater) Hemodynamically instability, defined by the attending physician Pregnant or breastfeeding Have a known allergy to either medication Used of prescription or illicit opioids within the previous week Patients with a chronic pain disorder, defined as use of any analgesic medication on more days than not during the four weeks preceding the acute episode of pain
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elliott Chinn, DO
Phone
612-873-3508
Email
elliott.chinn@hcmed.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elliott Chinn, DO
Organizational Affiliation
Hennepin County Medical Center, Minneapolis
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hennepin County Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55415
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elliott Chinn, DO
Phone
612-873-3508
Email
elliott.chinn@hcmed.org

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16301253
Citation
Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005 Dec;101(6):1738-1749. doi: 10.1213/01.ANE.0000186348.86792.38.
Results Reference
background
PubMed Identifier
26184397
Citation
Kranke P, Jokinen J, Pace NL, Schnabel A, Hollmann MW, Hahnenkamp K, Eberhart LH, Poepping DM, Weibel S. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. Cochrane Database Syst Rev. 2015 Jul 16;(7):CD009642. doi: 10.1002/14651858.CD009642.pub2.
Results Reference
background
PubMed Identifier
26044546
Citation
Ventham NT, Kennedy ED, Brady RR, Paterson HM, Speake D, Foo I, Fearon KC. Efficacy of Intravenous Lidocaine for Postoperative Analgesia Following Laparoscopic Surgery: A Meta-Analysis. World J Surg. 2015 Sep;39(9):2220-34. doi: 10.1007/s00268-015-3105-6.
Results Reference
background
PubMed Identifier
23044681
Citation
Sun Y, Li T, Wang N, Yun Y, Gan TJ. Perioperative systemic lidocaine for postoperative analgesia and recovery after abdominal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum. 2012 Nov;55(11):1183-94. doi: 10.1097/DCR.0b013e318259bcd8. Erratum In: Dis Colon Rectum. 2013 Feb;52(2):271.
Results Reference
background
PubMed Identifier
21061107
Citation
Vigneault L, Turgeon AF, Cote D, Lauzier F, Zarychanski R, Moore L, McIntyre LA, Nicole PC, Fergusson DA. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anaesth. 2011 Jan;58(1):22-37. doi: 10.1007/s12630-010-9407-0.
Results Reference
background
PubMed Identifier
18844267
Citation
Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. Br J Surg. 2008 Nov;95(11):1331-8. doi: 10.1002/bjs.6375.
Results Reference
background
PubMed Identifier
27752626
Citation
Fitzpatrick BM, Mullins ME. Intravenous lidocaine for the treatment of acute pain in the emergency department. Clin Exp Emerg Med. 2016 Jun 30;3(2):105-108. doi: 10.15441/ceem.15.103. eCollection 2016 Jun.
Results Reference
background
PubMed Identifier
21714904
Citation
Soleimanpour H, Hassanzadeh K, Mohammadi DA, Vaezi H, Esfanjani RM. Parenteral lidocaine for treatment of intractable renal colic: a case series. J Med Case Rep. 2011 Jun 29;5:256. doi: 10.1186/1752-1947-5-256.
Results Reference
background
PubMed Identifier
22559856
Citation
Soleimanpour H, Hassanzadeh K, Vaezi H, Golzari SE, Esfanjani RM, Soleimanpour M. Effectiveness of intravenous lidocaine versus intravenous morphine for patients with renal colic in the emergency department. BMC Urol. 2012 May 4;12:13. doi: 10.1186/1471-2490-12-13.
Results Reference
background
PubMed Identifier
26704774
Citation
Firouzian A, Alipour A, Rashidian Dezfouli H, Zamani Kiasari A, Gholipour Baradari A, Emami Zeydi A, Amini Ahidashti H, Montazami M, Hosseininejad SM, Yazdani Kochuei F. Does lidocaine as an adjuvant to morphine improve pain relief in patients presenting to the ED with acute renal colic? A double-blind, randomized controlled trial. Am J Emerg Med. 2016 Mar;34(3):443-8. doi: 10.1016/j.ajem.2015.11.062. Epub 2015 Dec 1.
Results Reference
background
PubMed Identifier
25147364
Citation
Vahidi E, Shakoor D, Aghaie Meybodi M, Saeedi M. Comparison of intravenous lidocaine versus morphine in alleviating pain in patients with critical limb ischaemia. Emerg Med J. 2015 Jul;32(7):516-9. doi: 10.1136/emermed-2014-203944. Epub 2014 Aug 21.
Results Reference
background
PubMed Identifier
29741660
Citation
Clattenburg EJ, Nguyen A, Yoo T, Flores S, Hailozian C, Louie D, Herring AA. Intravenous Lidocaine Provides Similar Analgesia to Intravenous Morphine for Undifferentiated Severe Pain in the Emergency Department: A Pilot, Unblinded Randomized Controlled Trial. Pain Med. 2019 Apr 1;20(4):834-839. doi: 10.1093/pm/pny031.
Results Reference
background
PubMed Identifier
30819520
Citation
Chinn E, Friedman BW, Naeem F, Irizarry E, Afrifa F, Zias E, Jones MP, Pearlman S, Chertoff A, Wollowitz A, Gallagher EJ. Randomized Trial of Intravenous Lidocaine Versus Hydromorphone for Acute Abdominal Pain in the Emergency Department. Ann Emerg Med. 2019 Aug;74(2):233-240. doi: 10.1016/j.annemergmed.2019.01.021. Epub 2019 Feb 26.
Results Reference
background
Links:
URL
https://www.cdc.gov/nchs/data/databriefs/db43.pdf
Description
Emergency Department Visits for Chest Pain and Abdominal Pain: United States, 1999-2008

Learn more about this trial

High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department

We'll reach out to this number within 24 hrs